Abstract
Heart failure (HF) is one of the major challenges in modern healthcare. Researches focused on new biological markers can significantly improve early detection and selection of effective therapeutic methods for patients with cardiovascular diseases (CVD). In recent years, matrix metalloproteinases (MMPs) are actively studied in cardiology. These proteolytic enzymes have stable structure. They are capable of breaking down peptide bonds in most extracellular matrix components. The objective of this review was to assess current experimental and clinical data on MMP-2 as a new diagnostic and prognostic marker in heart failure. MMP-2 is considered a key protease involved in heart remodeling. Elevated MMP-2 in the heart can lead to unfavorable ventricular remodeling and systolic heart dysfunction, even without other lesions. Clinical studies highlight significance of MMP-2 as a biomarker in diagnosis and prognosis of HF. Future research can provide more obvious data on feasibility of MMP-2 as a laboratory tool for diagnosing and assessing the risk in patients with HF. Further studies are also needed to explore the impact of MMP-2 inhibitors on morbidity and mortality in cardiovascular diseases.

This publication has 58 references indexed in Scilit: